Strides Pharma Science Limited
NSE: STAR · Pharmaceuticals
Snapshot
Unlock Strides Pharma Science Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Strides Pharma Science Limited is a global pharmaceutical company that develops, manufactures, and markets a wide range of generic and branded pharmaceutical products. The company operates through pharmaceutical and biopharmaceutical segments, offering diverse dosage forms including tablets, capsules, liquids, and topical treatments.
Business Model
The company generates revenue through the sale of generic pharmaceutical products across international markets and branded generics focused on chronic therapies. It serves both retail and institutional channels, providing treatments for infectious diseases and various chronic health conditions.
Growth Outlook
Growth is driven by the expansion of its branded generics portfolio in chronic therapy areas and the continued supply of essential medicines to institutional markets. The company leverages its diverse manufacturing capabilities to maintain a competitive presence in global pharmaceutical markets.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from international health authorities, where non-compliance could lead to import bans or facility audits.
- Pricing Pressure. Intense competition in the global generics market often leads to significant price erosion and margin compression.
- Supply Chain Volatility. Dependence on external suppliers for active pharmaceutical ingredients exposes the company to potential disruptions and cost fluctuations.
- Currency Risk. As a global exporter, the company is susceptible to foreign exchange volatility which can impact reported earnings and profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Strides Pharma Science Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹5,213 Cr
TTM · consolidated
NET PROFIT
₹637 Cr
TTM · consolidated
EPS
₹66.91
TTM · consolidated
RETURN ON EQUITY
20.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
22.9%
TTM · consolidated
P/E
15.5×
Q2 FY27 · consolidated
EV/EBITDA
10.4x
Q2 FY27 · consolidated
EBITDA MARGIN
20.7%
TTM · consolidated
NET PROFIT MARGIN
9.4%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.5x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Strides Pharma Science LimitedSTAR | ₹9,557 Cr | 15.5× | 10.43 | 11.3% | 20.7% | 20.6% | 22.9% | +10.9% |
Procter & Gamble Health LimitedPGHL | ₹9,674 Cr | 27.1× | 19.66 | 44.9% | 33.7% | 67.2% | 84.2% | -5.5% |
Blue Jet Healthcare Ltd.BLUEJET | ₹9,353 Cr | 36.5× | 26.79 | -27.5% | 39.2% | 18.8% | 25.0% | -24.7% |
Sanofi Consumer Healthcare India Ltd.SANOFICONR | ₹8,107 Cr | 29.0× | 19.51 | 22.7% | 39.9% | 92.5% | 113.0% | -27.3% |
Aarti Pharmalabs LimitedAARTIPHARM | ₹8,060 Cr | 31.4× | 17.95 | 13.4% | 22.9% | 11.9% | 14.6% | +4.3% |
Symbiotec Pharmalab LimitedSYMBIOTEC | ₹7,871 Cr | — | — | — | 27.0% | — | — | — |
As of Q2 FY27
Financials
Strides Pharma Science Limited
NSE: STAR · Pharmaceuticals
Snapshot
Unlock Strides Pharma Science Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Strides Pharma Science Limited is a global pharmaceutical company that develops, manufactures, and markets a wide range of generic and branded pharmaceutical products. The company operates through pharmaceutical and biopharmaceutical segments, offering diverse dosage forms including tablets, capsules, liquids, and topical treatments.
Business Model
The company generates revenue through the sale of generic pharmaceutical products across international markets and branded generics focused on chronic therapies. It serves both retail and institutional channels, providing treatments for infectious diseases and various chronic health conditions.
Growth Outlook
Growth is driven by the expansion of its branded generics portfolio in chronic therapy areas and the continued supply of essential medicines to institutional markets. The company leverages its diverse manufacturing capabilities to maintain a competitive presence in global pharmaceutical markets.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from international health authorities, where non-compliance could lead to import bans or facility audits.
- Pricing Pressure. Intense competition in the global generics market often leads to significant price erosion and margin compression.
- Supply Chain Volatility. Dependence on external suppliers for active pharmaceutical ingredients exposes the company to potential disruptions and cost fluctuations.
- Currency Risk. As a global exporter, the company is susceptible to foreign exchange volatility which can impact reported earnings and profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Strides Pharma Science Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹5,213 Cr
TTM · consolidated
NET PROFIT
₹637 Cr
TTM · consolidated
EPS
₹66.91
TTM · consolidated
RETURN ON EQUITY
20.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
22.9%
TTM · consolidated
P/E
15.5x
Q2 FY27 · consolidated
EV/EBITDA
10.4x
Q2 FY27 · consolidated
EBITDA MARGIN
20.7%
TTM · consolidated
NET PROFIT MARGIN
9.4%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.5x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
As of Q2 FY27